English
中文
CAS:36791-04-5
Storage:Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity:HPLC≥98%
Appearance:White to off-white Solid
Manual Download
Examples of using this product（for reference only）
In Vivo
Mice
The network pharmacology and molecular docking assays were employed to predict the targets of anemoside B4's treatment of pneumonia. Two models (bacterial KP-infected mice and virus FM1-infected mice) were employed in our study. BALB/c mice were divided into six groups: control, model group (KP-induced pneumonia or FM1-induced pneumonia), anemoside B4 (B4)-treated group (2.5, 5, 10 mg), and positive drug group (ribavirin or ceftriaxone sodium injection).
Reference：He J, Yuan R, Cui X, Cui Y, Han S, Wang QQ, Chen Y, Huang L, Yang S, Xu Q, Zhao Y, Gao H. Anemoside B4 protects against Klebsiella pneumoniae- and influenza virus FM1-induced pneumonia via the TLR4/Myd88 signaling pathway in mice. Chin Med. 2020 Jul 2;15:68. doi: 10.1186/s13020-020-00350-w. PMID: 32625244; PMCID: PMC7330533.
